For sk-Hep1 cell line, EGF could not activate Src, but dasatinib could also reduce the activity of FAK, indicating dasatinib may interplay with other molecules to block the phosphorylation of FAK, and therefore inhibit the motility and invasion of HCC cells. The gene discussed is SRC; the disease is hepatocellular carcinoma.